These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A rational regulatory approach for positron emission tomography imaging probes: from "first in man" to NDA approval and reimbursement. Barrio JR; Marcus CS; Hung JC; Keppler JS Mol Imaging Biol; 2004; 6(6):361-7. PubMed ID: 15564146 [TBL] [Abstract][Full Text] [Related]
3. Satisfying the requirements of the Food and Drug Administration and Centers for Medicare and Medicare Services. Smith JJ; Henderson JA J Am Coll Radiol; 2008 Mar; 5(3):189-92. PubMed ID: 18312966 [TBL] [Abstract][Full Text] [Related]
5. The food and drug administration and molecular imaging agents: potential challenges and opportunities. Henderson JA; Alexander BC; Smith JJ J Am Coll Radiol; 2005 Oct; 2(10):833-40. PubMed ID: 17411943 [TBL] [Abstract][Full Text] [Related]
6. Anticancer Drug Development: The Way Forward. Connors T Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985 [TBL] [Abstract][Full Text] [Related]
7. The diffusion of new imaging technologies: a molecular imaging prospective. Hillman BJ J Am Coll Radiol; 2006 Jan; 3(1):33-7. PubMed ID: 17412004 [TBL] [Abstract][Full Text] [Related]
8. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals. Harapanhalli RS Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596 [TBL] [Abstract][Full Text] [Related]
9. Assessment and approval of medical devices used in diagnostic imaging in the United States. Johnson GC Isr J Med Sci; 1986; 22(7-8):505-18. PubMed ID: 3536797 [TBL] [Abstract][Full Text] [Related]
10. Molecular imaging and personalized medicine: an uncertain future. Nunn AD Cancer Biother Radiopharm; 2007 Dec; 22(6):722-39. PubMed ID: 18158763 [TBL] [Abstract][Full Text] [Related]
11. Rising costs of medical imaging spur debate. Rowan K J Natl Cancer Inst; 2008 Dec; 100(23):1665-7. PubMed ID: 19033570 [No Abstract] [Full Text] [Related]
13. Positron emission tomography: a financial and operational analysis. Conti PS; Keppler JS; Halls JM AJR Am J Roentgenol; 1994 Jun; 162(6):1279-86. PubMed ID: 8191981 [TBL] [Abstract][Full Text] [Related]
14. Operation of a radiopharmacy for a clinical trial. Norenberg JP; Petry NA; Schwarz S Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594 [TBL] [Abstract][Full Text] [Related]
15. Using imaging biomarkers to accelerate drug development and clinical trials. Pien HH; Fischman AJ; Thrall JH; Sorensen AG Drug Discov Today; 2005 Feb; 10(4):259-66. PubMed ID: 15708744 [TBL] [Abstract][Full Text] [Related]
16. Roadmap for reform: outlook for imaging under accountable care. Lund IV; Hartman J Radiol Manage; 2011; 33(6):22-6; quiz 27-8. PubMed ID: 22235736 [TBL] [Abstract][Full Text] [Related]
17. The emergence of diagnostic imaging technologies in breast cancer: discovery, regulatory approval, reimbursement, and adoption in clinical guidelines. Gold LS; Klein G; Carr L; Kessler L; Sullivan SD Cancer Imaging; 2012 Jan; 12(1):13-24. PubMed ID: 22275726 [TBL] [Abstract][Full Text] [Related]